Journal
CANCER CELL
Volume 3, Issue 1, Pages 63-74Publisher
CELL PRESS
DOI: 10.1016/S1535-6108(02)00238-6
Keywords
-
Categories
Funding
- NCI NIH HHS [R21-CA89888, P30-CA68485, R01-CA89674, P50-CA90949, R01-CA70937, R01-CA88076, R01-CA58508] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA070937, R21CA089888, P30CA068485, R01CA058508, P50CA090949, R01CA089674, R01CA088076] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The objective of this study was to target drug delivery to radiation-induced neoantigens, which include activated receptors within the tumor vasculature. These responses include posttranslational changes in pre-existing proteins, which can be discovered by phage-displayed peptide libraries administered to mice bearing irradiated tumors. Phage-displayed peptides recovered from irradiated tumors included the amino acid sequence RGDGSSV. This peptide binds to integrins within the tumor microvasculature. Immunohistochemical staining of irradiated tumors showed accumulation of fibrinogen receptor alpha(2b)beta(3) integrin. We studied tumor targeting efficiency of ligands to radiation-induced alpha(2b)beta(3). Radiopharmaceuticals were localized to irradiated tumors by use of alpha(2b)beta(3) ligands conjugated to nanoparticles and liposomes. Fibrinogen-conjugated nanoparticles bind to the radiation-activated receptor, obliterate tumor blood flow, and significantly increase regression and growth delay in irradiated tumors. Radiation-guided drug delivery to tumor blood vessels is a novel paradigm for targeted drug delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available